{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:19:23Z","timestamp":1784132363751,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semdiagpath.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1053\/j.semdp.2016.11.002","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T03:00:19Z","timestamp":1481079619000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["A new molecular paradigm in mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1053","volume":"34","author":[{"given":"Kojo S.J.","family":"Elenitoba-Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"279","key":"10.1053\/j.semdp.2016.11.002_bib1","doi-asserted-by":"crossref","first-page":"279ra39","DOI":"10.1126\/scitranslmed.3010302","article-title":"Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells","volume":"7","author":"Watanabe","year":"2015","journal-title":"Sci Transl Med"},{"issue":"117","key":"10.1053\/j.semdp.2016.11.002_bib2","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.semdp.2016.11.002_bib3","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1053\/j.semdp.2016.11.002_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"10.1053\/j.semdp.2016.11.002_bib5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"10.1053\/j.semdp.2016.11.002_bib6","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"issue":"9","key":"10.1053\/j.semdp.2016.11.002_bib7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"7463","key":"10.1053\/j.semdp.2016.11.002_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000018423","article-title":"Mycosis fungoides: review of epidemiological observations","volume":"201","author":"Morales Suarez-Varela","year":"2000","journal-title":"Dermatology"},{"issue":"11","key":"10.1053\/j.semdp.2016.11.002_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/ajh.22139","article-title":"Cutaneous T-cell lymphoma. 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Wilcox","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1084\/jem.20011578","article-title":"V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites","volume":"195","author":"Marculescu","year":"2002","journal-title":"J Exp Med"},{"issue":"6","key":"10.1053\/j.semdp.2016.11.002_bib12","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1128\/MCB.17.6.3125","article-title":"Cryptic signals and the fidelity of V(D)J joining","volume":"17","author":"Lewis","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1053\/j.semdp.2016.11.002_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev-immunol-031210-101329","article-title":"Mechanisms that promote and suppress chromosomal translocations in lymphocytes","volume":"29","author":"Gostissa","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1053\/j.semdp.2016.11.002_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2014-03-562751","article-title":"PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events","volume":"124","author":"Mendes","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.semdp.2016.11.002_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ng.2874","article-title":"RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","volume":"46","author":"Papaemmanuil","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"10.1053\/j.semdp.2016.11.002_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cell.2015.07.009","article-title":"RAG represents a widespread threat to the lymphocyte genome","volume":"162","author":"Teng","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.semdp.2016.11.002_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1053\/j.semdp.2016.11.002_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ceb.2007.10.003","article-title":"E2F-associated chromatin modifiers and cell cycle control","volume":"19","author":"Blais","year":"2007","journal-title":"Curr Opin Cell Biol"},{"issue":"10","key":"10.1053\/j.semdp.2016.11.002_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome\u00a0\u2013 biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"7143","key":"10.1053\/j.semdp.2016.11.002_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature05915","article-title":"The complex language of chromatin regulation during transcription","volume":"447","author":"Berger","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.semdp.2016.11.002_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell."},{"issue":"12","key":"10.1053\/j.semdp.2016.11.002_bib23","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.autrev.2013.07.002","article-title":"CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance","volume":"12","author":"Romo-Tena","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1053\/j.semdp.2016.11.002_bib24","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1084\/jem.176.6.1595","article-title":"Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes","volume":"176","author":"Linsley","year":"1992","journal-title":"J Exp Med"},{"issue":"2","key":"10.1053\/j.semdp.2016.11.002_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of Sezary syndrome by targeting a novel CTLA4:cd28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genom Med"},{"issue":"13","key":"10.1053\/j.semdp.2016.11.002_bib26","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","article-title":"PLCG1 mutations in cutaneous T-cell lymphomas","volume":"123","author":"Vaque","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"issue":"9","key":"10.1053\/j.semdp.2016.11.002_bib28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/2159-8290.CD-15-1297","article-title":"Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma","volume":"6","author":"Mishra","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1053\/j.semdp.2016.11.002_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2008-01-131185","article-title":"Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia\/lymphoma","volume":"112","author":"Hidaka","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.semdp.2016.11.002_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0092-8674(00)80240-8","article-title":"The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells","volume":"89","author":"Zheng","year":"1997","journal-title":"Cell"},{"issue":"8","key":"10.1053\/j.semdp.2016.11.002_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1471-4906(03)00177-7","article-title":"TCR-induced NF-kappaB activation: a crucial role for Carma1, Bcl10 and MALT1","volume":"24","author":"Thome","year":"2003","journal-title":"Trends Immunol"},{"issue":"5870","key":"10.1053\/j.semdp.2016.11.002_bib32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"7","key":"10.1053\/j.semdp.2016.11.002_bib33","first-page":"1931","article-title":"Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions","volume":"9","author":"Zhang","year":"1994","journal-title":"Oncogene"},{"issue":"12","key":"10.1053\/j.semdp.2016.11.002_bib34","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.4049\/jimmunol.178.12.7767","article-title":"Negative regulation of TCR signaling by NF-kappaB2\/p100","volume":"178","author":"Legarda-Addison","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"10.1053\/j.semdp.2016.11.002_bib35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.semdp.2016.11.002_bib36","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.semdp.2016.11.002_bib37","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.semdp.2016.11.002_bib38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","article-title":"Tofacitinib: a review of its use in adult patients with rheumatoid arthritis","volume":"73","author":"Scott","year":"2013","journal-title":"Drugs"},{"issue":"15","key":"10.1053\/j.semdp.2016.11.002_bib39","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s40265-015-0470-2","article-title":"Ruxolitinib: a review in polycythaemia vera","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"issue":"14","key":"10.1053\/j.semdp.2016.11.002_bib40","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.semdp.2016.11.002_bib41","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.24203","article-title":"A three-signal model of T-cell lymphoma pathogenesis","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.semdp.2016.11.002_bib43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.0022-202X.2004.23586.x","article-title":"Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma","volume":"124","author":"Vonderheid","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1053\/j.semdp.2016.11.002_bib44","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.4049\/jimmunol.158.10.4984","article-title":"Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation","volume":"158","author":"McCusker","year":"1997","journal-title":"J Immunol"},{"issue":"21","key":"10.1053\/j.semdp.2016.11.002_bib45","first-page":"1681","article-title":"CD28 mutations in peripheral T-cell lymphomagenesis and progression","volume":"124","author":"Rohr","year":"2014","journal-title":"Blood Annu Meet Abstr"},{"issue":"4","key":"10.1053\/j.semdp.2016.11.002_bib46","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.semdp.2016.11.002_bib47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of Sezary syndrome by targeting a novel CTLA4:cd28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genom Med"},{"issue":"6","key":"10.1053\/j.semdp.2016.11.002_bib48","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.1302951","article-title":"Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner","volume":"192","author":"Zhang","year":"2014","journal-title":"J Immunol"},{"issue":"5","key":"10.1053\/j.semdp.2016.11.002_bib49","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/jid.2013.488","article-title":"The role of IL-32 in cutaneous T-cell lymphoma","volume":"134","author":"Suga","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1053\/j.semdp.2016.11.002_bib50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/jid.2011.293","article-title":"Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome","volume":"132","author":"van der Fits","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"13","key":"10.1053\/j.semdp.2016.11.002_bib51","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J Exp Med"},{"issue":"5039","key":"10.1053\/j.semdp.2016.11.002_bib52","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1126\/science.1840704","article-title":"Identification of a zinc finger protein that inhibits IL-2 gene expression","volume":"254","author":"Williams","year":"1991","journal-title":"Science."},{"issue":"18","key":"10.1053\/j.semdp.2016.11.002_bib53","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.semdp.2016.11.002_bib54","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.semdp.2016.11.002_bib55","first-page":"3328","article-title":"STAT3\/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. Clinical cancer research: an official journal of the American Association for","volume":"22","author":"Vieyra-Garcia","year":"2016","journal-title":"Cancer Res"},{"issue":"10","key":"10.1053\/j.semdp.2016.11.002_bib56","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/ni.3252","article-title":"The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells","volume":"16","author":"Nakatsukasa","year":"2015","journal-title":"Nat Immunol"},{"issue":"6035","key":"10.1053\/j.semdp.2016.11.002_bib57","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1126\/science.1204351","article-title":"Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation","volume":"332","author":"Jenkins","year":"2011","journal-title":"Science"},{"issue":"21","key":"10.1053\/j.semdp.2016.11.002_bib58","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.semdp.2016.11.002_bib59","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clinical Cancer Res"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"31","key":"10.1053\/j.semdp.2016.11.002_bib61","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6230","key":"10.1053\/j.semdp.2016.11.002_bib62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"15","key":"10.1053\/j.semdp.2016.11.002_bib63","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/leu.2009.198","article-title":"Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines","volume":"24","author":"Wilcox","year":"2010","journal-title":"Leukemia"},{"issue":"26","key":"10.1053\/j.semdp.2016.11.002_bib65","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.semdp.2016.11.002_bib66","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.semdp.2016.11.002_bib67","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2009-12-260216","article-title":"Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma","volume":"116","author":"Kamstrup","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.semdp.2016.11.002_bib68","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.semdp.2016.11.002_bib69","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1182\/blood-2015-02-625251","article-title":"Mogamulizumab: 2 birds, 1 stone","volume":"125","author":"Wilcox","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.semdp.2016.11.002_bib70","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1053\/j.semdp.2016.11.002_bib71","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jid.2016.01.038","article-title":"Evaluation of immunophenotypic and molecular biomarkers for sezary syndrome using standard operating procedures: a multicenter study of 59 patients","volume":"136","author":"Boonk","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1053\/j.semdp.2016.11.002_bib72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2015.4701","article-title":"Palbociclib (PD0332991) \u2013 a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development","volume":"2","author":"Clark","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2016.11.002_bib73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ajh.23568","article-title":"Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma","volume":"89","author":"Jones","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1053\/j.semdp.2016.11.002_bib74","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jid.2016.03.024","article-title":"Identification of Gene Mutations and Fusion Genes in Patients with Sezary Syndrome","volume":"136","author":"Prasad","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1053\/j.semdp.2016.11.002_bib75","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2007-09-112698","article-title":"Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia","volume":"111","author":"Saddler","year":"2008","journal-title":"Blood"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257016300922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257016300922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T06:06:14Z","timestamp":1692597974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257016300922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0740257016300922"],"URL":"https:\/\/doi.org\/10.1053\/j.semdp.2016.11.002","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new molecular paradigm in mycosis fungoides and S\u00e9zary syndrome","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semdp.2016.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}